Washington: Prescribing antipsychotic drugs to kids and young adults having behavioural problems or mood disorders could put them at a risk for acquiring type 2 diabetes, a study has showed.
The Vanderbilt University Medical Center study shows that young people using medications like risperidone, quetiapine, aripiprazol and olanzapine led to a threefold increased risk of developing type 2 diabetes within the first year of taking the drug.
Senior author Wayne A. Ray, Ph.D., professor of Preventive Medicine, said that while other studies have shown an increased risk for type 2 diabetes associated with the use atypical antipsychotic medications, this is the first large, well-designed study to look at the risk in children.
The authors noted that the use of these drugs for non-psychosis-related mood, attention or behavioral disorders in youth/children now accounts for the majority of prescriptions.
Ray said that as they wanted to address this question of risk for indications for which there were therapeutic alternatives, they deliberately excluded those taking antipsychotics for schizophrenia and other psychoses; thus, our entire sample consisted of patients for whom there were alternatives to antipsychotics.
State-provided, de-identified medical records were examined for TennCare youths ages 6-24 from 1996 through 2007.
During that time children and youth who were prescribed treatment with atypical antipsychotics for attention, behavioral or mood disorders, were compared with similar youth prescribed approved medications for those disorders.
Even with the further elimination of certain disorders that are commonly associated with diabetes, like polycystic ovarian syndrome, those taking antipsychotics had triple the risk of developing type 2 diabetes in the following year, with the risk increasing further as cumulative dosages increased. The increased risk persisted for at least a year after the medications were stopped.
Ray and his colleagues point out developing type 2 diabetes is still rare in this age group. Of the nearly 29,000 children and youth in the antipsychotic medication group and 14,400 children in the control group, 106 were ultimately diagnosed and treated for type 2 diabetes.
The study has been published in the journal JAMA Psychiatry.